These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 17909043

  • 1. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 2. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW.
    J Urol; 2003 Jul 01; 170(1):246-52. PubMed ID: 12796698
    [Abstract] [Full Text] [Related]

  • 3. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 01; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 4. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 5. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.
    Prostate Cancer Prostatic Dis; 2005 Nov 15; 8(3):253-9. PubMed ID: 15999121
    [Abstract] [Full Text] [Related]

  • 7. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ.
    Cancer Res; 2005 May 01; 65(9):3707-15. PubMed ID: 15867366
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K.
    J Bone Miner Res; 2003 Mar 01; 18(3):482-92. PubMed ID: 12619933
    [Abstract] [Full Text] [Related]

  • 9. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.
    Cancer Res; 2010 Oct 01; 70(19):7610-9. PubMed ID: 20841471
    [Abstract] [Full Text] [Related]

  • 10. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, Nilsson S.
    Acta Oncol; 2005 Oct 01; 44(6):644-50. PubMed ID: 16165924
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 12. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
    Ji YB, Zhou JH, Zuo MX, You QD.
    Yao Xue Xue Bao; 2008 Aug 01; 43(8):811-8. PubMed ID: 18956773
    [Abstract] [Full Text] [Related]

  • 13. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.
    Cancer Biol Ther; 2009 Jun 01; 8(12):1109-16. PubMed ID: 19652526
    [Abstract] [Full Text] [Related]

  • 14. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 15. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ.
    Cancer Res; 2008 Mar 15; 68(6):1916-26. PubMed ID: 18339873
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D.
    Mol Pharmacol; 2007 Jan 15; 71(1):333-43. PubMed ID: 17050806
    [Abstract] [Full Text] [Related]

  • 17. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
    Tenta R, Sourla A, Lembessis P, Koutsilieris M.
    Anticancer Res; 2006 Jan 15; 26(1A):283-91. PubMed ID: 16475708
    [Abstract] [Full Text] [Related]

  • 18. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S.
    Clin Cancer Res; 2003 Nov 01; 9(14):5380-5. PubMed ID: 14614023
    [Abstract] [Full Text] [Related]

  • 19. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.
    J Cell Physiol; 2007 May 01; 211(2):533-43. PubMed ID: 17192846
    [Abstract] [Full Text] [Related]

  • 20. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI.
    Br J Cancer; 2001 Apr 20; 84(8):1126-34. PubMed ID: 11308265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.